Teva launches new cancer medicines in EU and US

Teva has provided an update on its oncology portfolio, highlighting the recent launch of two important new biologic therapies for neutropenia.

Lonquex, which was recently granted European regulatory approval, has been introduced in Germany as part of an EU-wide rollout of the long-acting drug, while the short-acting therapy Granix was also launched in the US.

Both products represent new treatment options that can reduce the duration of severe neutropenia in patients with non-myeloid malignancies, who are receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

The therapies have proven their safety and efficacy in clinical trials conducted by Teva.

Dr Rob Koremans, president and chief executive officer of Teva Global Specialty Medicines, said: "By making these treatment options available to physicians and their patients, our goal is to make a meaningful difference in the lives of those with cancer."

This comes after the company announced the departure of its chief executive officer Jeremy Levin last month, with Eyal Desheh taking over on an interim basis.